This is a preprint.
Enhancing CRISPR prime editing by reducing misfolded pegRNA interactions
- PMID: 37645936
- PMCID: PMC10462064
- DOI: 10.1101/2023.08.14.553324
Enhancing CRISPR prime editing by reducing misfolded pegRNA interactions
Update in
-
Enhancing CRISPR prime editing by reducing misfolded pegRNA interactions.Elife. 2024 Jun 7;12:RP90948. doi: 10.7554/eLife.90948. Elife. 2024. PMID: 38847802 Free PMC article.
Abstract
CRISPR prime editing (PE) requires a Cas9 nickase-reverse transcriptase fusion protein (known as PE2) and a prime editing guide RNA (pegRNA), an extended version of a standard guide RNA (gRNA) that both specifies the intended target genomic sequence and encodes the desired genetic edit. Here we show that sequence complementarity between the 5' and the 3' regions of a pegRNA can negatively impact its ability to complex with Cas9, thereby potentially reducing PE efficiency. We demonstrate this limitation can be overcome by a simple pegRNA refolding procedure, which improved ribonucleoprotein-mediated PE efficiencies in zebrafish embryos by up to nearly 25-fold. Further gains in PE efficiencies of as much as 6-fold could also be achieved by introducing point mutations designed to disrupt internal interactions within the pegRNA. Our work defines simple strategies that can be implemented to improve the efficiency of PE.
Conflict of interest statement
Competing Financial Interests Statement J.K.J. has, or had during the course of this research, financial interests in several companies developing gene editing technology: Beam Therapeutics, Blink Therapeutics, Chroma Medicine, Editas Medicine, EpiLogic Therapeutics, Excelsior Genomics, Hera Biolabs, Monitor Biotechnologies, Nvelop Therapeutics (f/k/a ETx, Inc.), Pairwise Plants, Poseida Therapeutics, SeQure Dx, Inc., and Verve Therapeutics. J.K.J.’s interests were reviewed and are managed by Massachusetts General Hospital and Mass General Brigham in accordance with their conflict of interest policies. J.K.J. is a co-inventor on various patents and patent applications that describe gene editing and epigenetic editing technologies. K.P. has a financial interest in SeQure Dx, Inc. K.P.ʼs interests and relationships have been disclosed to Massachusetts General Hospital and Mass General Brigham in accordance with their conflict of interest policies. The remaining authors declare no competing interests.
Figures
References
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials